Skip to main content

Advertisement

SpringerLink
Log in

Osteopontin Expression is Associated with Improved Survival in Patients with Pancreatic Adenocarcinoma

  • Pancreatic Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Osteopontin (OPN) is a secreted protein of the extracellular matrix. It has been used as a marker for tumor aggressiveness and correlated with clinical outcomes in several solid tumors, such as liver, lung, and breast. We determined the OPN expression and its influence on survival in patients with resected pancreatic adenocarcinoma.

Methods

Tissue microarrays were constructed from 245 resected pancreatic adenocarcinomas. Immunohistochemical staining for OPN was undertaken and compared to normal pancreas (n = 12). OPN expression was then correlated with patient demographics, tumor size, grade, node, and margin status. Survival curves were created by the Kaplan–Meier method and compared by log rank analysis.

Results

In total, 181 (74 %) of pancreatic adenocarcinoma tissues expressed OPN compared to 7 (58 %) of normal controls (p = 0.004). Expression was observed predominantly in the cytoplasm of the tumor cells. The median and 2 year overall survival was longer when OPN was expressed (17.1 vs. 11.6 months, and 38 vs. 24 %, respectively, p = 0.04). Multivariate analysis showed OPN expression and T stage to be independent predictors of overall survival, while other histopathologic factors such as tumor grade, tumor size, and nodal status were not.

Conclusions

These results suggest that the presence of OPN expression in pancreatic adenocarcinoma may have a protective effect independent of tumor stage. This emphasizes the importance of the interaction between pancreatic cancer cells and their stromal elements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J Gastroenterol. 2011;17:867–97.

    Article  PubMed  Google Scholar 

  3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.

    Article  PubMed  CAS  Google Scholar 

  4. Farrow B, Berger DH, Rowley D. Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2. J Surg Res. 2009;156:155–60.

    Article  PubMed  CAS  Google Scholar 

  5. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60:861–8.

    Article  PubMed  Google Scholar 

  6. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. Exp Oncol. 2010;32:128–31.

    PubMed  CAS  Google Scholar 

  7. Kolb A, Kleef J, Guweidi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther. 2005;4:740–6.

    Article  PubMed  CAS  Google Scholar 

  8. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 2007;67:5141–7.

    Article  PubMed  CAS  Google Scholar 

  9. Fedarko NS, Jain A, Karadag A, Fisher LW. SIBLING interactions with complement factor H and pro-matrixmetalloproteinases. Presented at the Third International Conference on Osteopontin and SIBLING Proteins, San Antonio, TX, 2002.

  10. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer. 2000;83:156–63.

    Article  PubMed  CAS  Google Scholar 

  11. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene. 1996;13:97–104.

    PubMed  CAS  Google Scholar 

  12. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56:571–80.

    Article  PubMed  CAS  Google Scholar 

  13. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119–27.

    Article  PubMed  CAS  Google Scholar 

  14. Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteopontin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res. 2004;10:1588–96.

    Article  PubMed  CAS  Google Scholar 

  15. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417–27.

    PubMed  CAS  Google Scholar 

  16. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487–91.

    PubMed  CAS  Google Scholar 

  17. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.

  18. De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med. 2005;129:1100–5.

    PubMed  Google Scholar 

  19. Ahmed M, Kundu GC. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NK-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer. 2010;9:101.

    Article  PubMed  Google Scholar 

  20. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239–49.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Research supported by the 2010 AACR-FNAB Fellows Grant for Translational Pancreatic Cancer Research, grant 10-30-14-COLL (A. L. C.) and NCI CA13325-01 (M. B.).

Author information

Authors and Affiliations

  1. Department of Surgery, The Ohio State University, Columbus, OH, USA

    Amy L. Collins MD & Lavina Malhotra MD

  2. Department of Pathology, The Ohio State University, Columbus, OH, USA

    Jonathan Rock MD & Wendy L. Frankel MD

  3. Division of Surgical Oncology, The Ohio State University College of Medicine, Columbus, OH, USA

    Mark Bloomston MD

Authors
  1. Amy L. Collins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Rock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lavina Malhotra MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wendy L. Frankel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Bloomston MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Bloomston MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collins, A.L., Rock, J., Malhotra, L. et al. Osteopontin Expression is Associated with Improved Survival in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol 19, 2673–2678 (2012). https://doi.org/10.1245/s10434-012-2337-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2337-z

Keywords

Search

Navigation